Treatment with secukinumab is highly effective in clearing nail psoriasis: long‐term results from the TRANSFIGURE clinical trial

British Journal of DermatologyVolume 184, Issue 3 p. e92-e92 Plain Language SummaryFree Access Treatment with secukinumab is highly effective in clearing nail psoriasis: long-term results from the TRANSFIGURE clinical trial First published: 05 March 2021 https://doi.org/10.1111/bjd.19769AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text full-text accessPlease review our Terms and Conditions Use check box below share version article.I have read accept Wiley Online Library UseShareable LinkUse link a this article your friends colleagues. Learn more.Copy URL Share linkShare onEmailFacebookTwitterLinked InRedditWechat Abstract Psoriasis common skin disease that causes scaly patches on skin, can also affect nails. affects significant number people throughout world. The prevalence symptoms psoriasis ranges less than 40% patients mild 50–70% those severe forms. Nail associated pain impaired finger mobility function. Also, due its visible exposed nature, it negative impact daily lives patients. was phase III including 198 Trials are designed provide final evidence whether treatment be approved for use general public. It conducted multiple countries around world Australia, Belgium, Czech Republic, Denmark, Germany, Greece, Spain, UK USA. study evaluate efficacy (effectiveness) safety medicine called moderate-to-severe involvement. This first specifically psoriasis. primary endpoint (the outcome measured by researchers) analysed improvement severity Secukinumab proved superior placebo (a ‘dummy drug’ doesn’t contain any active medication) respect. Secondary endpoints patients’ quality life, again more placebo, after 16 weeks treatment. These improvements continued over time sustained following up 2.5 years. demonstrate therapy not only clearance, but provides control re-emphasizes role as an different shown safe use, low rates serious adverse effects. Linked Article: Reich et al. Br J Dermatol 2021; 184:425–436. Volume184, Issue3March 2021Pages RelatedInformation